Articles By Jack Cush, MD
Anti-IL-5 Success in Eosinophilic Granulomatosis with Polyangiitis
The NEJM reports success when using mepolizumab (anti-IL-5 monoclonal antibody) in a 52 week study of patients with eosinophilic granulomatosis with polyangiitis (EGPA).
Read Article
Actemra - First FDA Approved Drug for Giant Cell Arteritis
The FDA has approved subcutaneous tocilizumab for use in Giant Cell Arteritis based on the phase III GiACTA study that demonstrated that TCZ with steroids was superior to steroid therapy alone.
Read Article
IL-6 Inhibitor Kevzara Granted FDA Approval for Rheumatoid Arthritis
The FDA has approved sarilumab (Kevzara), a new IL-6 inhibitor co-developed by Regeneron and Sanofi's, for use in adults with moderate to severe rheumatoid arthritis (RA).
Read Article
Anti-Sclerostin Drug Hampered by Heart Problems
Reuters reports that FDA approval of romosozumab (brand name Evenity) may be held up because of higher rates of cardiac events seen in a late-stage clinical trial.
Read Article
The RheumNow Week in Review – 17 May 2017
Dr. Jack Cush reviews highlights and updates from the past week on RheumNow.com:
Read Article
My Approach to Difficult RA
Patients are labeled as having “difficult RA" when: 1) we are frustrated, 2) it's too late, 3) we've run out of options or 4) the relationship is failing. We see them, but don’t quite know what to do with them.
Read Article
Non-Prescribed Opioid Abuse by Young Adults
Journal of Addiction Medicine reported that young adults often are "self-medicated" to manage pain.
Read Article
Educational Intervention Facilitates Treat-to-Target Management in Rheumatoid Arthritis
Treat-to-target education through group-based quality improvement sessions can result in wider use of treat-to-target in practice, according to researchers.
Read Article
NOR-SWITCH Study Validates Biosimilar Use in Multiple Indications
Lancet reports the results of the NOR-SWITCH study - a trial performed in Norway as biosimilars were being introduced.
Read Article
Steroid Injections for Knee Osteoarthritis May Promote Cartilage Loss
Treatment of knee osteoarthritis (with synovitis) with an injection of a corticosteroid every three months over two years resulted in significantly greater cartilage volume loss and no significant difference in knee pain compared to patients who received a placebo injection, according to a study
Read Article
